Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations
ReviewHumans
- Design
- Review
- Subjects
- 48 studies, of which 47 were randomised controlled trials
- Dose used in the study
- The included trials used about 150 to 700 mg, once or twice a day
- Duration
- From 3 days to 53 weeks
- What was measured
- A systematic review, following PRISMA 2020, of randomised trials in patients. It groups outcomes as neuropsychiatric, neurological, bodily pain and function, gut and internal organs, and blood markers.
What the authors reported
The authors rated most of the included trials as good quality on the Joanna Briggs Institute tool, and two as fair. They reported that palmitoylethanolamide was well tolerated across the trials, with no relevant adverse events.
Limits of this study
A systematic review without a pooled analysis. The authors note that the trials differ in method and in formulation, which makes them hard to compare. The entry was checked against the article page and the Crossref record. Funding and conflicts were not visible on the page checked.
Source
doi:10.1016/j.bbih.2024.100927
Entry checked against the article page at the publisher (ScienceDirect), with the citation from Crossref on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.